Search Results - "van Dongen, J.J.M"

Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: Reference patterns for age‐related changes and disease‐induced shifts by van Lochem, E.G., van der Velden, V.H.J., Wind, H.K., te Marvelde, J.G., Westerdaal, N.A.C., van Dongen, J.J.M.

“…Background The abundance of monoclonal antibodies (mAb) and the routine use of quadruple stainings in flow cytometry allow stepwise analysis of bone marrow…”
Get full text

probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders by Pedreira, C.E, Costa, E.S, Almeida, J, Fernandez, C, Quijano, S, Flores, J, Barrena, S, Lecrevisse, Q, Van Dongen, J.J.M, Orfao, A

“…Multiparameter flow cytometry has become an essential tool for monitoring response to therapy in hematological malignancies, including B-cell chronic…”
Get full text

Cluster analysis of genomic ETV6 – RUNX1 ( TEL – AML1 ) fusion sites in childhood acute lymphoblastic leukemia by von Goessel, H, Jacobs, U, Semper, S, Krumbholz, M, Langer, T, Keller, T, Schrauder, A, van der Velden, V.H.J, van Dongen, J.J.M, Harbott, J, Panzer-Grümayer, E.R, Schrappe, M, Rascher, W, Metzler, M

“…Abstract Fusion between ETV6 and RUNX1 defines the largest genetic subgroup in childhood ALL. The genomic fusion site, unique to individual patients and…”
Get full text

A-220 Standardized flow cytometry for the detection and characterization of circulating CTCL cells: Update on a multicenter study by de Bie, F.J., van der Sluijs-Gelling, A.J., Najidh, S., Lau, C., Orfao, A., van Dongen, J.J.M., Almeida, J., Vermeer, M.H.

Get full text

Impact of blood storage and sample handling on quality of high dimensional flow cytometric data in multicenter clinical research by Diks, A.M., Bonroy, C., Teodosio, C., Groenland, R.J., de Mooij, B., de Maertelaere, E., Neirynck, J., Philippé, J., Orfao, A., van Dongen, J.J.M., Berkowska, M.A.

“…Obtaining reliable and reproducible high quality data in multicenter clinical research settings requires design of optimal standard operating procedures. While…”
Get full text

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes by van Dongen, J J M, Lhermitte, L, Böttcher, S, Almeida, J, van der Velden, V H J, Flores-Montero, J, Rawstron, A, Asnafi, V, Lécrevisse, Q, Lucio, P, Mejstrikova, E, Szczepański, T, Kalina, T, de Tute, R, Brüggemann, M, Sedek, L, Cullen, M, Langerak, A W, Mendonça, A, Macintyre, E, Martin-Ayuso, M, Hrusak, O, Vidriales, M B, Orfao, A

“…Most consensus leukemia & lymphoma antibody panels consist of lists of markers based on expert opinions, but they have not been validated. Here we present the…”
Get full text

EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols by Kalina, T, Flores-Montero, J, van der Velden, V H J, Martin-Ayuso, M, Böttcher, S, Ritgen, M, Almeida, J, Lhermitte, L, Asnafi, V, Mendonça, A, de Tute, R, Cullen, M, Sedek, L, Vidriales, M B, Pérez, J J, te Marvelde, J G, Mejstrikova, E, Hrusak, O, Szczepański, T, van Dongen, J J M, Orfao, A

“…The EU-supported EuroFlow Consortium aimed at innovation and standardization of immunophenotyping for diagnosis and classification of hematological…”
Get full text

EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations by Langerak, A W, Groenen, P J T A, Brüggemann, M, Beldjord, K, Bellan, C, Bonello, L, Boone, E, Carter, G I, Catherwood, M, Davi, F, Delfau-Larue, M-H, Diss, T, Evans, P A S, Gameiro, P, Garcia Sanz, R, Gonzalez, D, Grand, D, Håkansson, Å, Hummel, M, Liu, H, Lombardia, L, Macintyre, E A, Milner, B J, Montes-Moreno, S, Schuuring, E, Spaargaren, M, Hodges, E, van Dongen, J J M

“…PCR-based immunoglobulin (Ig)/T-cell receptor (TCR) clonality testing in suspected lymphoproliferations has largely been standardized and has consequently…”
Get full text

Clonality analysis for antigen receptor genes: Preliminary results from the biomed-2 concerted action PL 96-3936 by Van Krieken, J.H.J.M., Langerak, A.W., San Miguel, J.F., Parreira, A., Smith, J.L., Morgan, G.M., Kneba, M., MacIntyre, E.A., Van Dongen, J.J.M.

Get full text

From big flow cytometry datasets to smart diagnostic strategies: The EuroFlow approach by Pedreira, C.E., Costa, E. Sobral da, Lecrevise, Q., Grigore, G., Fluxa, R., Verde, J., Hernandez, J., van Dongen, J.J.M., Orfao, A.

“…The rise in the analytical speed of mutiparameter flow cytometers made possible by the introduction of digital instruments, has brought up the possibility to…”
Get full text

EuroFlow: Resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine by van Dongen, J J M, Orfao, A

Get full text

Estimating human age from T-cell DNA rearrangements by Zubakov, D., Liu, F., van Zelm, M.C., Vermeulen, J., Oostra, B.A., van Duijn, C.M., Driessen, G.J., van Dongen, J.J.M., Kayser, M., Langerak, A.W.

“…Predicting human phenotypes from genotypes is a newly emerging field with relevance for personalized medicine [1] and forensics [2]. However, only a few…”
Get full text

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008 by Brüggemann, M, Schrauder, A, Raff, T, Pfeifer, H, Dworzak, M, Ottmann, O G, Asnafi, V, Baruchel, A, Bassan, R, Benoit, Y, Biondi, A, Cavé, H, Dombret, H, Fielding, A K, Foà, R, Gökbuget, N, Goldstone, A H, Goulden, N, Henze, G, Hoelzer, D, Janka-Schaub, G E, Macintyre, E A, Pieters, R, Rambaldi, A, Ribera, J-M, Schmiegelow, K, Spinelli, O, Stary, J, von Stackelberg, A, Kneba, M, Schrappe, M, van Dongen, J J M

“…Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia…”
Get full text

Expression and Intracellular Localization of the Human N-acetylmuramyl-L-alanine Amidase, a Bacterial Cell Wall–Degrading Enzyme by Hoijer, M.A., Melief, M.J., Calafat, J., Roos, D., van den Beemd, R.W.M., van Dongen, J.J.M., Hazenberg, M.P.

“…N-acetylmuramyl-L-alanine amidase (NAMLAA) specifically degrades peptidoglycan, which is a major component of bacterial cell walls with strong inflammatory…”
Get full text

Standardized flow cytometry (EuroFlow) demonstrates heterogeneous T-cell origin of Sézary lymphoma cells by Najidh, Safa, van der Sluijs-Gelling, A.J., Zoutman, W.H., Tensen, C.P., van Hall, T.H., Almeida, J., van Dongen, J.J.M., Vermeer, M.H.

Get full text

Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia by Flohr, T, Schrauder, A, Cazzaniga, G, Panzer-Grümayer, R, van der Velden, V, Fischer, S, Stanulla, M, Basso, G, Niggli, F K, Schäfer, B W, Sutton, R, Koehler, R, Zimmermann, M, Valsecchi, M G, Gadner, H, Masera, G, Schrappe, M, van Dongen, J J M, Biondi, A, Bartram, C R

“…Detection of minimal residual disease (MRD) is the most sensitive method to evaluate treatment response and one of the strongest predictors of outcome in…”
Get full text

IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL by Kuiper, R P, Waanders, E, van der Velden, V H J, van Reijmersdal, S V, Venkatachalam, R, Scheijen, B, Sonneveld, E, van Dongen, J J M, Veerman, A J P, van Leeuwen, F N, Geurts van Kessel, A, Hoogerbrugge, P M

“…Relapse is the most common cause of treatment failure in pediatric acute lymphoblastic leukemia (ALL) and is often difficult to predict. To explore the…”
Get full text

Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia by Denys, B, van der Sluijs-Gelling, A J, Homburg, C, van der Schoot, C E, de Haas, V, Philippé, J, Pieters, R, van Dongen, J J M, van der Velden, V H J

“…Most current treatment protocols for acute lymphoblastic leukemia (ALL) include minimal residual disease (MRD) diagnostics, generally based on PCR analysis of…”
Get full text

Basal [Ca.sup.2+] signaling is particularly increased in mutated chronic lymphocytic leukemia by Muggen, A.F, Pillai, S.Y, Kil, L.P, van Zelm, M.C, van Dongen, J.J.M, Hendriks, R.W, Langerak, A.W

“…On the basis of somatic hypermutation status of their B-cell antigen receptor (BCR) genes, chronic lymphocytic leukemia (CLL) patients can be divided into…”
Get full text

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells by de Vries, J F, Zwaan, C M, De Bie, M, Voerman, J S A, den Boer, M L, van Dongen, J J M, van der Velden, V H J

“…We investigated whether the newly developed antibody (Ab) -targeted therapy inotuzumab ozogamicin (CMC-544), consisting of a humanized CD22 Ab linked to…”
Get full text